Cipla Profit & Loss Annual

Trade

BSE: 500087 | NSE: CIPLA | ISIN: INE059A01026 | Sector: Biotechnology & Drugs

1,507.85 +21.55 (1.45%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	25,774.09	22,753.12	21,763.34	19,159.59
Total Revenue	25,774.09	22,753.12	21,763.34	19,159.59
Costof Revenue Total	8,819.57	9,314.24	9,560.75	8,328.64
Gross Profit	16,954.52	13,438.88	12,202.59	10,830.95
Selling/ General/ Admin Expenses Total	4,310.04	7,507.04	6,908.86	6,031.69
Depreciation/ Amortization	1,051.02	1,017.83	987.83	1,000.57
Unusual Expense( Income)	194.82	309.57	241.32	64.54
Other Operating Expenses Total	6,353.43	511.60	463.91	399.33
Total Operating Expense	20,728.88	19,047.03	18,430.60	15,960.05
Operating Income	5,045.21	3,706.09	3,332.74	3,199.54
Interest Inc( Exp) Net- Non- Op Total	-898.80	2,968.40	908.30	212.10
Other Net	746.57	33.84	61.02	66.30
Net Income Before Taxes	5,701.90	4,038.35	3,493.27	3,290.06
Provisionfor Income Taxes	1,546.59	1,202.86	933.80	888.76
Net Income After Taxes	4,155.31	2,835.49	2,559.47	2,401.30
Minority Interest	-32.17	-30.98	-29.90	16.36
Equity In Affiliates	-15.90	-26.00	-128.20	-127.90
Net Income Before Extra Items	4,121.55	2,801.91	2,516.75	2,404.87
Net Income	4,121.55	2,801.91	2,516.75	2,404.87
Income Availableto Com Excl Extra Ord	4,121.55	2,801.91	2,516.75	2,404.87
Income Availableto Com Incl Extra Ord	4,121.55	2,801.91	2,516.75	2,404.87
Dilution Adjustment	0.00	-	-	-
Diluted Net Income	4,121.55	2,801.91	2,516.75	2,404.87
Diluted Weighted Average Shares	80.80	80.76	80.74	80.73
Diluted EPS Excluding Extra Ord Items	51.01	34.69	31.17	29.79
DPS- Common Stock Primary Issue	13.00	8.50	5.00	5.00
Diluted Normalized EPS	52.77	37.37	33.28	30.35
Research Development	-	3,853.90	2,656.80	1,327.30
Interest Exp( Inc) Net- Operating Total	-	13.60	22.50	25.50
Gain( Loss)on Saleof Assets	-	15.80	86.80	30.10